LeonardJosephApplemanMD
Oncology • Pittsburgh, PAGenitourinary Oncology
Associate Professor, Medicine, University of Pittsburgh School of Medicine
Dr. Appleman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5115 Centre Avenue
5150 Centre AVE, Suite 560
Pittsburgh, PA 15232Phone+1 412-692-4724- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1995 - 1998
New York University School of MedicineClass of 1995
Certifications & Licensure
PA State Medical License 2006 - 2024
MA State Medical License 1998 - 2006- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- A Study of Imatinib and Docetaxel in Prostate Cancer Start of enrollment: 2005 Aug 01
- Study of Oxaliplatin and Taxotere in Prostate Cancer Start of enrollment: 2004 Nov 01
- MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasect...Leonard J Appleman, Se Eun Kim, Wayne B Harris, Sumanta K Pal, Michael R Pins, Jill Kolesar, Neeraj Agarwal, Rahul A Parikh, Daniel A Vaena, Christopher W Ryan, Mehmoo...> ;Journal of Clinical Oncology. 2024 Mar 26
- 2 citationsXaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.Kelly, W., Danila, D., Lin, C., Lee, J., Matsubara, N., Ward, P., Armstrong, A., Pook, D., Kim, M., Dorff, T., Fischer, S., Lin, Y., Horvath, L., Sumey, C., Yang, Z., ...> ;Cancer Discovery. 2024 Jan 12
- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.Petrylak, D., Eigl, B., George, S., Heath, E., Hotte, S., Chism, D., Nabell, L., Picus, J., Cheng, S., Appleman, L., Sonpavde, G., Morgans, A., Pourhosseini, P., Wu, R...> ;Clinical Cancer Research. 2024 Jan 5
- Join now to see all
Lectures
- Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metasta...2019 ASCO Annual Meeting - 6/1/2019
- Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
The Society for Immunotherapy of Cancer (SITC) Invites You to Attend the Virtual Press Briefing of the Society’s 36th Anniversary Annual MeetingNovember 2nd, 2021
Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCCJune 14th, 2019
No Benefit from Pazopanib in Advanced Kidney Cancer After Surgery to Remove MetastasesJune 3rd, 2019- Join now to see all
Hospital Affiliations
UPMC Presbyterian ShadysidePittsburgh, Pennsylvania
UPMC Magee-Womens HospitalPittsburgh, Pennsylvania- Shadyside CampusPittsburgh, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
